Achaogen (AKAO) Getting Somewhat Favorable News Coverage, Report Finds

News coverage about Achaogen (NASDAQ:AKAO) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Achaogen earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.2462914845717 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the media stories that may have impacted Accern Sentiment’s analysis:

Shares of AKAO traded up $0.23 during mid-day trading on Tuesday, hitting $12.44. 400,743 shares of the company’s stock were exchanged, compared to its average volume of 1,221,912. Achaogen has a twelve month low of $9.83 and a twelve month high of $27.49. The firm has a market cap of $554.15, a price-to-earnings ratio of -3.92 and a beta of 1.02. The company has a quick ratio of 4.83, a current ratio of 4.83 and a debt-to-equity ratio of 0.08.

Achaogen (NASDAQ:AKAO) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.21). Achaogen had a negative return on equity of 83.14% and a negative net margin of 1,124.10%. The business had revenue of $1.87 million for the quarter, compared to analyst estimates of $1.18 million. research analysts predict that Achaogen will post -3.47 earnings per share for the current fiscal year.

Several brokerages recently commented on AKAO. William Blair restated an “outperform” rating on shares of Achaogen in a research report on Wednesday, February 28th. ValuEngine upgraded shares of Achaogen from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Zacks Investment Research downgraded shares of Achaogen from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. Needham & Company LLC restated a “buy” rating and issued a $20.00 price target (down previously from $29.00) on shares of Achaogen in a research report on Wednesday, February 28th. Finally, Leerink Swann restated an “outperform” rating on shares of Achaogen in a research report on Sunday, March 4th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $23.56.

In related news, insider Kenneth J. Hillan sold 4,606 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $10.67, for a total transaction of $49,146.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Robert W. Duggan acquired 527,396 shares of the firm’s stock in a transaction that occurred on Friday, March 2nd. The shares were purchased at an average cost of $10.31 per share, with a total value of $5,437,452.76. Following the completion of the acquisition, the insider now owns 5,697,752 shares in the company, valued at approximately $58,743,823.12. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 810,717 shares of company stock valued at $8,739,717 and have sold 10,089 shares valued at $110,576. 8.36% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Achaogen (AKAO) Getting Somewhat Favorable News Coverage, Report Finds” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at

Achaogen Company Profile

Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

Insider Buying and Selling by Quarter for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with's FREE daily email newsletter.

Leave a Reply